ArticleNeuroImage. Clinical2017
Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.
Article in NeuroImage. Clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Neuroimaging and machine learning for studying the pathways from mild cognitive impairment to alzheimer's disease: a systematic review.BMC neurology · 2023Pooled it
- Brain volumes discriminate clinical dementia rating scale categories.Scientific reports · 2025Article
- Association between cerebrospinal fluid clusterin and biomarkers of Alzheimer's disease pathology in mild cognitive impairment: a longitudinal cohort study.Frontiers in aging neuroscience · 2023Article
- Brain atrophy pattern in patients with mild cognitive impairment: MRI study.Translational neuroscience · 2022Article
- Comparing different approaches for operationalizing subjective cognitive decline: impact on syndromic and biomarker profiles.Scientific reports · 2021Article
- Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features.Scientific reports · 2020Article
- Visual rating versus volumetry of regional brain atrophy and longitudinal changes over a 5-year period in an elderly population.Brain and behavior · 2020Article
- Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- Review
- Visualizing modules of coordinated structural brain atrophy during the course of conversion to Alzheimer's disease by applying methodology from gene co-expression analysis.NeuroImage. Clinical · 2019Article
- Longitudinal Mapping of Cortical Thickness Measurements: An Alzheimer's Disease Neuroimaging Initiative-Based Evaluation Study.Journal of Alzheimer's disease : JAD · 2019Article
- Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline.AJNR. American journal of neuroradiology · 2019Article
- Colocalization of neurons in optical coherence microscopy and Nissl-stained histology in Brodmann's area 32 and area 21.Brain structure & function · 2019Article
- Pre-Mild Cognitive Impairment: Can Visual Memory Predict Who Rapidly Convert to Mild Cognitive Impairment?Psychiatry investigation · 2018Article
- The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
backgroundA disease severity index (SI) for Alzheimer's disease (AD) has been proposed that summarizes MRI-derived structural measures into a single score using multivariate data analysis.
objectivesTo longitudinally evaluate the use of the SI to monitor disease progression and predict future progression to AD in mild cognitive impairment (MCI). Further, to investigate the association between longitudinal change in the SI and cognitive impairment, Apolipoprotein E (APOE) genotype as well as the levels of cerebrospinal fluid amyloid-beta 1-42 (Aβ) peptide.
methodsThe dataset included 195 AD, 145 MCI and 228 control subjects with annual follow-up for three years, where 70 MCI subjects progressed to AD (MCI-p). For each subject the SI was generated at baseline and follow-ups using 55 regional cortical thickness and subcortical volumes measures that extracted by the FreeSurfer longitudinal stream.
resultsMCI-p subjects had a faster increase of the SI over time (
conclusionsLongitudinal changes in the SI reflect structural brain changes and can identify MCI patients at risk of progression to AD. Disease-related brain structural changes are influenced independently by APOE genotype and amyloid pathology. The SI has the potential to be used as a sensitive tool to predict future dementia, monitor disease progression as well as an outcome measure for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.